Epidemiology of esophageal cancer: update in global trends, etiology and risk factors

Uhlenhopp, Dustin; Then, Eric O.; Sunkara, Tagore; Gaduputi, Vinaya

doi:10.1007/s12328-020-01237-x

Cited by 473 publications

(431 citation statements)

References 74 publications

Supporting

Mentioning

365

Contrasting

Unclassified

Order By: Relevance

“…Esophageal cancer is a common gastrointestinal malignancy that causes more than 500,000 cancer deaths per year (1). The 5-year survival rate of patients with esophageal cancer is less than 25% (1). Developing a better treatment strategy for esophageal cancer is important.…”

mentioning

confidence: 99%

A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation

Kao

Hsu

2021

In Vivo

View full text Add to dashboard Cite

Background: Preservation of organ function is important in cancer treatment. The 'watch-and-wait' strategy is an important approach in management of esophageal cancer. However, clinical imaging cannot accurately evaluate the presence or absence of residual tumor after neoadjuvant chemoradiation. As a result, using radiomics to predict complete pathological response in esophageal cancer has gained in popularity in recent years. Given that the characteristics of patients and sites vary considerably, a meta-analysis is needed to investigate the predictive power of radiomics in esophageal cancer. Patients and Methods: PRISMA guidelines were used to conduct this study. PubMed, Cochrane, and Embase were searched for literature review. The quality of the selected studies was evaluated by the radiomics quality score. I 2 score and Cochran's Q test were used to evaluate heterogeneity between studies. A funnel plot was used for evaluation of publication bias. Results: A total of seven articles were collected for this meta-analysis. The pooled area under the receiver operating characteristics curve of the seven selected articles for predicting pathological complete response in eosphageal cancer patient was quite high, achieving a pooled value of 0.813 (95% confidence intervaI=0.761-0.866). The radiomics quality score ranged from −2 to 16 (maximum score: 36 points). Three out of the seven studies used machine learning algorithms, while the others used traditional biostatistics methods. One of the seven studies used morphology class features, while four studies used first-order features, and five used second-order features. Conclusion: Using radiomics to predict complete pathological response after neoadjuvant chemoradiotherapy in esophageal cancer is feasible. In the future, prospective, multicenter studies should be carried out for predicting pathological complete response in patients with esophageal cancer.

show abstract

mentioning

confidence: 99%

A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation

Kao

Hsu

2021

In Vivo

View full text Add to dashboard Cite

show abstract

“…ESCC is the most common type of EC, with a 15 to 20% 5-year survival rate worldwide, though in some countries the 5-year survival rate has improved by 15%. A key contributor to the high mortality rate of ESCC is late-stage diagnosis, as nearly 40% of incidences have metastasized by the time of diagnosis [29,30]. Histologically, EC is classified into two main subtypes, EAC and ESCC.…”

Section: Background Of Esccmentioning

confidence: 99%

Heterogeneity Analysis of Esophageal Squamous Cell Carcinoma in Cell Lines, Tumor Tissues and Patient-Derived Xenografts

Laster

Nie

et al. 2021

J. Cancer

View full text Add to dashboard Cite

Esophageal Squamous Cell Carcinoma (ESCC) is the predominant type of Esophageal Cancer (EC), accounting for nearly 88% of EC incidents worldwide. Importantly, it is also a life-threatening cancer for patients diagnosed in advanced stages, with only a 20% 5-year survival rate due to a limited number of actionable targets and therapeutic options. Increasing evidence has shown that inter-tumor and intra-tumor heterogeneity are widely distributed across ESCC tumor tissues. In our work, multi-omics data from ESCC cell lines, tumor tissue, normal tissue and Patient-Derived Xenograft (PDX) tissues were analyzed to investigate the heterogeneity among ESCC samples at the DNA, RNA, and protein level. We identified enrichment of ECM-receptor interaction and Focal adhesion pathways from the subset of protein-coding genes with non-silent mutations in ESCC patients. We also found that TP53, TTN, KMT2D, CSMD3, DNAH5, MUC16 and DST are the most frequently mutated genes in ESCC patient samples. Out of the identified genes, TP53 is the most frequently mutated, with 84 distinct non-silent mutation variants. We observed that p.R248Q, p.R175G/H, and p.R273C/H are the most common TP53 mutation variants. The diversity of TP53 mutations reveal its importance in ESCC progression and may also provide promising targets for precision therapeutics. Additionally, we identified the Olfactory transduction as the top signaling pathway, enriched from genes uniquely expressed in The Cancer Genome Atlas (TCGA)-ESCC patient tumor tissues, which may provide implications for the exact roles of the corresponding genes in ESCC. Cyclic nucleotide-gated channel subunit beta 1(CNGB1), a gene belonging to the Olfactory transduction pathway, was found exclusively overexpressed in ESCC. Expression of CNGB1 could serve as a marker, indicating potential diagnostic or therapeutic value. Finally, we investigated heterogeneity in the context of the ESCC PDX model, which is an emerging tool used to predict drug response and recapitulate tumor behavior in vivo. We observed trans-species heterogeneity in as high as 75% of the identified proteins, indicating that the ambiguity of proteins should be addressed by specific strategies to avoid drawing false conclusions. The identification and characterization of gene mutation and expression heterogeneity across different ESCC datasets, including various novel TP53 mutations, ECM-receptor interaction, Focal adhesion, and Olfactory transduction pathways (CNGB1), provide researchers with evidence and implications for accurate research and precision therapeutic development.

show abstract

“…Esophageal carcinoma (EC) is one of the most lethal malignancies worldwide, with high morbidities and mortalities 1,2 . Histologically, esophageal adenocarcinoma and esophageal squamous cell carcinoma (ESCC) are the main types of EC, accounting for 90% of all EC cases 3 .…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β‐catenin signaling pathway and EMT in esophageal squamous cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Evidence from previous studies showed that the dysregulation of microRNA (miR) is frequently associated with tumor progression. The aberrant miR‐210 expression has been identified in a variety of tumors. However, its biological roles in esophageal squamous cell carcinoma (ESCC) still need further elucidation. Thus, in the current study we explore the roles of miR‐210 in ESCC progression. The findings of our study reveal that miR‐210 is down‐regulated in ESCC, which indicates poor prognosis and aggressive tumor progression. Moreover, miR‐210 restoration was found to enhance ESCC viability, invasion, and migration abilities. F‐Box only protein 31 (FBXO31) was confirmed to be one of the targets of miR‐210 in ESCC cells. Results also revealed that miR‐210 played crucial roles in regulating ESCC cell epithelial‐mesenchymal transition (EMT) and Wnt/β‐catenin signaling. In conclusion, data show that miR‐210 serves as an anti‐ESCC miR via down‐regulation of FBXO31 and regulation of EMT and Wnt signaling, suggesting that the miR‐210/FBXO31 axis may function as promising therapeutic targets and effective prognostic markers for ESCC patients.

show abstract

Epidemiology of esophageal cancer: update in global trends, etiology and risk factors

Cited by 473 publications

References 74 publications

A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation

A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation

Heterogeneity Analysis of Esophageal Squamous Cell Carcinoma in Cell Lines, Tumor Tissues and Patient-Derived Xenografts

MicroRNA‐210 targets FBXO31 to inhibit tumor progression and regulates the Wnt/β‐catenin signaling pathway and EMT in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About